• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

TetraLogic Pharmaceuticals

edit

TetraLogic Pharmaceuticals is a privately held biopharmaceutical company that discovers and develops small molecule drugs that modulate programmed cell death pathways to treat debilitating diseases and conditions. The company’s Smac Mimetics neutralize critical blocks in the apoptosis pathway to selectively destroy cancer cells. Its Necrostatin drugs block critical steps in the process leading to necrosis, enabling cell survival in a wide range of diseases and injuries where necrosis is a critical component of pathology.

Recent Milestones

edit

• 
  TetraLogic Pharmaceuticals received $6M in Series C funding. (5/24/11)
  Posted 5/24/11 at 3:55am via streetinsider.com
• 
  TetraLogic Pharmaceuticals received $23M in Series C funding. (1/4/11)
  Posted 1/5/11 at 7:25pm via dowjones.com
• 
  TetraLogic Pharmaceuticals received $5M in Series C funding. (9/27/10)
  Posted 9/27/10 at 11:24pm via dowjones.com
• 
  TetraLogic Pharmaceuticals received $32M in Series C funding. (8/10/10)
  Posted 8/10/10 at 5:26pm via fiercebiotech.com
• 
  TetraLogic Pharmaceuticals added John M. Gill as Founder, President, CEO.
  Posted 8/10/10 at 5:26pm

Videos

Screenshots

edit

Sources

1. TetraLogic nabs $32M round for lead cancer therapy Read more: TetraLogic nabs $32M round for lead cancer therapy (fiercebiotech.com) [edit]
2. TetraLogic Pharma Boosts Series C To $37M With Pfizer Ventures Capital (fis.dowjones.com) [edit]
3. TetraLogic Pulls Down $23M Series C Tranche For Cancer Trials (fis.dowjones.com) [edit]
4. TetraLogic Closes $6 Million Series C-1 Investment with Nextech Invest Ltd (streetinsider.com) [edit]